Search

Displaying results 2971 - 2980 of 10000 in total
  1. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric … In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent

  2. Drug

    Fexapotide

    go.drugbank.com/drugs/DB05493
    Investigational

    NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed.

    Categories: Drugs Used in Benign Prostatic Hypertrophy
  3. Drug

    Ibutilide

    go.drugbank.com/drugs/DB00308
    Approved

    Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations.

    Synonyms: N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide
  4. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    Aripiprazole lauroxil is a long-acting injectable atypical antipsychotic drug used in the treatment of schizophrenia in adult patients. … It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289].

  5. Drug

    Umeclidinium

    go.drugbank.com/drugs/DB09076
    ApprovedInvestigational

    COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than … [A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product.

  6. Drug

    Panitumumab

    go.drugbank.com/drugs/DB01269
    ApprovedInvestigational

    Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. … Panitumumab was granted FDA approval on 27 September 2006.[L17663]

  7. Drug

    Revakinagene taroretcel

    go.drugbank.com/drugs/DB05344
    ApprovedInvestigational

    (rhCNTF) (NTC-201-6A cell line) for surgical intravitreal placement. … [A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2.

    Categories: Complex MixturesSynonyms: An allogeneic human adult retinal pigment epithelial (RPE) cell line stably transfected with a plasmid, Allogeneic human adult retinal pigment epithelial (RPE) cell line stably transfected with a plasmid encoding human ciliary neurotrophic factor (CNTF).
  8. Drug

    Proflavine

    go.drugbank.com/drugs/DB01123
    ApprovedInvestigational

    Topical antiseptic used mainly in wound dressings.

    Mixtures: Kerr 100 Triple Dye Dispos-A
  9. Drug

    Pentetreotide

    go.drugbank.com/drugs/DB12602
    ApprovedWithdrawn

    Pentetreotide has been used in trials studying the diagnosis of Cushing's syndrome.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Etoposide

    go.drugbank.com/drugs/DB00773
    ApprovedInvestigational

    A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. … This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding.

    Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: INJECTION ETOPOSIDE CS 100MG IN 5ML